MIODx is developing immune repertoire sequencing-based tests to predict whether patients will have a favorable response to immunotherapy and whether they will have adverse immune reactions as a result of the therapy.
MIODx announced today that it has signed an exclusive license for two key immunotherapy technologies from the University of California, San Francisco (UCSF).
MIODx announced today the addition of Jill Hagenkord MD to the company's Board of Directors. Dr. Hagenkord recently joined Color Genomics as its Chief Medical Officer (CMO).
MIODx announced today the establishment of the company's Science Advisory Board.
MIODx, a pioneer in cancer biomarker detection, has closed its seed round with $1.5 mln.